



EuroSIDA Newsletter

June 2022

**Dear EuroSIDA Study Investigators, friends,
and colleagues,**

The EuroSIDA Coordinating Centre sends you many summer greetings and as always, we want to repeat our appreciation for the continued excellent work and important contributions to the EuroSIDA study. Your efforts are very highly valued and influential to our high level of scientific research.

We wish you a pleasant summer and look forward to continued collaboration in the second half of 2022 and beyond.

Study updates

Cohort 11

The enrolment of Cohort 11 closed on the 1st of May 2022 and we have received more than 1500 enrolment forms. We will make an exception for three sites and conduct additional data download next year. In total, we hope to have around 1700 participants enrolled in Cohort 11. We thank all the sites for your tremendous contribution to the study.

Dataset 50 (DS50)

We are excited to announce the collection of dataset number 50 this year which is a great achievement and milestone for all of us. There are EuroSIDA sites

that have contributed data to all 50 datasets, since 1994! The data submission will open on 1st September and 1st October for REST and REDCap sites respectively. The deadline for data submission will be 1st December 2022.

Clinical Reporting Form Updates

Covid 19 form

The Covid-19 form was introduced for participants who had been admitted to the hospital for treatment of COVID-19. We have not received any new forms since our last update (total number of forms 109). For each form completed, 50 euros will be reimbursed for next year of submission.

You can read more about the form in the [COVID-19 eCRF Manual of Operations here](#).

Cabotegravir

In 2021, EuroSIDA started to collect detailed data on participants who receive treatment with injectable long-acting cabotegravir and/or long-acting rilpivirine. Data are collected annually in two separate REDCap forms. The sub-study will run for five years. We have not received any new participants initiating the treatment since our last update (total number of forms 13).

MISTRAL study

The MISTRAL study has reached the process of finalizing the data processing agreements (DPAs) and site agreements with sites. We are pleased that we have received ethics approvals from half of the 25 EuroSIDA sites that are participating in MISTRAL. As we are close to finalizing contracts and DPAs with many sites, we are equipped to initiate the study and expect to enroll participants from one to three sites during the summer.

For more information on the MISTRAL study [click here](#).

Reminders

We have sent letters regarding CD4 cell count measurements to sites that have provided CD4 values as percentages only and asked to submit the missing cell count values and units, as the value in percentage is inadequate for our data

collection. Therefore, we remind those sites kindly to submit the missing CD4 cell counts and units for the measurements within the REDCap project, EuroSIDA CD4 and HIV-RNA.

Please remember to update the EuroSIDA Coordinating Centre if there are staff changes. This allows all correspondence (information, newsletters, etc.) to be sent to the right contact person. It also allows the EuroSIDA Coordinating Centre to maintain the study group and correctly award co-authorship. Furthermore, if staff no longer work at your Centre or new staff members join your team, we will remove or assign REDCap access accordingly.

Reimbursement

The 2022 reimbursement process is being finalized and the payment will be made to all sites over the summer. We had hoped to finalize the process before summer, and we apologize for the inconvenience this may cause some of you.

Publications and Presentations

EuroSIDA reaches 323 Publications

Since our last newsletter in April 2022, the EuroSIDA study group has published one more publication and three manuscripts have been accepted for publication and are in press. We want to thank you for your significant contribution to the EuroSIDA study and the global community of people living with HIV.

Published

Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. Bastian Neesgaard. Lancet HIV. 2022:S2352-3018(22)00094-7. [Abstract](#)

In press

- ***Use of contraindicated antiretroviral drugs in HIV/HCV coinfecting persons receiving HCV treatment with direct-acting antivirals – results from the EuroSIDA study.*** Myroslava Nikolaichuk. HIV Medicine. 2022
- ***Observational Cohort Study of Rilpivirine (RPV) Utilization in Europe.*** Alessandro Cozzi-Lepri. AIDS Research and Therapy. 2022

- ***Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in persons living with HIV.*** Erich Stephen Tusch. AIDS. 2022

A list of all EuroSIDA publications can be found [here](#).

Furthermore, all RESPOND publications can be found [here](#).

RESPOND Presentation at the 12th International Workshop on HIV & Women, Virtual, 6-8 April 2022

- A poster presentation on '***Characteristics of Women Living with HIV in the RESPOND Cohort***' was presented by Jolie Hutchinson on behalf of the RESPOND Study Group. The presentation can be found [here](#).

EuroSIDA Investigators meeting in Glasgow, October 2022

We are excited to announce that we are planning to host our traditional annual EuroSIDA investigator meeting again, especially since the last one was almost three years ago! We will send out invitations to all EuroSIDA investigators to participate in the meeting which will take place during the HIV Glasgow conference in October.

We will dedicate the meeting to updates on the EuroSIDA, MISTRAL, and RESPOND studies, but more importantly, to see and greet you all in person again! More information regarding the meeting will be announced as we approach.

EuroSIDA Staff Update

Please say goodbye to an old colleague at CHIP.

Unfortunately, we will be saying goodbye to our IT specialist, **Erik Viuff Hansen** in the cohort team. It has truly been a pleasure to be working with him. We wish him well and thank him for his great contributions to CHIP and, the EuroSIDA study over the past many years.

We wish everyone in the EuroSIDA study a wonderful summer and we look forward to continuing the fantastic partnership we have with all of you!